Skip to main content

Pheochromocytoma clinical trials at UCSF
2 in progress, 1 open to new patients

  • Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

    open to eligible people ages 2 years and up

    This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.

    San Francisco, California

  • A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

    Sorry, in progress, not accepting new patients

    This clinical trial is designed to evaluate the effectiveness and collect additional safety information on Ultratrace® Iobenguane I 131 for the treatment of relapsed/refractory (to other treatment) malignant pheochromocytoma and paraganglioma. The purpose of this trial is to test the use of Ultratrace® iobenguane I 131 as a treatment for pheochromocytoma and paraganglioma type cancer. This Phase II study will help determine primarily if using the drug reduces the amount of blood pressure medication being taken as a result of the cancer and secondarily to determine such things as the effectiveness of the study drug in treating the cancer, additional safety measures, and to assess if the drug helps the quality of life and use of pain medication. All subjects will receive an imaging dose with scans followed by two therapy doses that are given 3 months apart.

    San Francisco, California and other locations